title: Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
abstract: The purpose was to validate the use of RUNX3 as a potential biomarker for detection of cancer in serum samples and to determine its sensitivity alone and in combination with p16, RASSF1A and CDH1 using methylation-specific polymerase chain reaction (MSP). We examined the promoter methylation status of RUNX3, p16, RASSF1A and CDH1 by MSP using the serum of 70 metastatic breast, non-small cell lung, gastric, pancreatic, colorectal or hepatocellular carcinomas. The DNA from 10 healthy serum controls was used to determine the specificity of methylation. According to our results, promoter hyper-methylation of RUNX3 was detected in the serum of 44 patients comprising breast 9/19 (47%), non-small cell lung 11/20 (55%), gastric 4/4 (100%), pancreatic 2/2 (100%), colorectal 11/17 (65%) and liver 7/8 (88%) carcinomas. Comparative figures for the other genes were as follows: p16 - 39/70 (7/19, 10/20, 2/4, 0/2, 12/17, 8/8); RASSF1A - 24/70 (8/19, 6/20, 1/4, 1/2, 4/17, 4/8); CDH1 - 10/70 (0/19, 4/20, 1/4, 1/2, 3/17, 1/8). Using a panel of four genes, hypermethylation of one or more genes was found in 62/70 samples (15/19, 19/20, 4/4, 2/2, 14/17, 8/8). A panel of three genes omitting RUNX3 detected hyper-methylation in only 50/70 samples. No methylation was detected in the 10 healthy serum controls. Thus, RUNX3 can be detected in the serum of a high proportion of advanced cancers. This suggests that serum hypermethylation of RUNX3 is at least as, or possibly more sensitive a marker, than other tumor suppressor genes currently under investigation. Inclusion of RUNX3 in gene panels can potentially increase the sensitivity of such panels for serum diagnosis of malignancies and warrants further study.
authors.affiliation: Department of Hematology-Oncology, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Republic of Singapore.
authors.forename: Sing-Huang
authors.initials: SH
authors.lastname: Tan
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ida
authors.forename: Quek-Choon
authors.initials: QC
authors.lastname: Lau
authors.forename: Boon-Cher
authors.initials: BC
authors.lastname: Goh
authors.forename: Wei-Shieng
authors.initials: WS
authors.lastname: Chieng
authors.forename: Marie
authors.initials: M
authors.lastname: Loh
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ito
mesh_terms: D050677:Core Binding Factor Alpha 3 Subunit / Q000235:genetics*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood*; D016147:Genes, Tumor Suppressor; D006801:Humans; D009362:Neoplasm Metastasis / Q000235:genetics*; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012680:Sensitivity and Specificity
chemical_list: D050677:Core Binding Factor Alpha 3 Subunit; D004273:DNA, Neoplasm; C493729:Runx3 protein, human